Ted W Johnson

Ted W Johnson

UNVERIFIED PROFILE

Are you Ted W Johnson?   Register this Author

Register author
Ted W Johnson

Ted W Johnson

Publications by authors named "Ted W Johnson"

Are you Ted W Johnson?   Register this Author

20Publications

961Reads

15Profile Views

Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.

ACS Med Chem Lett 2018 Sep 24;9(9):872-877. Epub 2018 Aug 24.

Pfizer Worldwide Research and Development, La Jolla Oncology, 10770 Science Center Drive, San Diego, California 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142052PMC
September 2018

Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib.

ACS Med Chem Lett 2018 Sep 18;9(9):878-883. Epub 2018 Jun 18.

Oncology Medicinal Sciences, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142050PMC
September 2018

Lipophilic Efficiency as an Important Metric in Drug Design.

J Med Chem 2018 08 17;61(15):6401-6420. Epub 2018 Apr 17.

Oncology Medicinal Chemistry , Pfizer Inc. , 10770 Science Center Drive , La Jolla , California 92121 , United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.8b00077DOI Listing
August 2018

Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners.

Angew Chem Int Ed Engl 2016 Mar 16;55(11):3590-5. Epub 2016 Feb 16.

Oncology Medicinal Chemistry, Pfizer, La Jolla, 10770 Science Center Drive, San Diego, CA, 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201509240DOI Listing
March 2016

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016

CNS Anticancer Drug Discovery and Development Conference White Paper.

Neuro Oncol 2015 Nov;17 Suppl 6:vi1-26

Kaiser Permanente, Redwood City, California, USA (V.A.L.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (V.A.L.); University of California, San Francisco, CA, USA (V.A.L.); SUNY Stony Brook University, Stony Brook, NY, USA (P.J.T.); Icahn School of Medicine at Mount Sinai, New York, NY, USA (J.M.G., M.R.B., A.C.D.); Columbia University Institute for Cancer Genetics, New York, NY, USA (A.I.); Fred Hutchinson Cancer Research Center, Seattle, WA, USA (P.J.P.); Genentech, Inc., South San Francisco, CA, USA (T.P.H.); University of Minnesota School of Pharmacy, Minneapolis, MN, USA (W.F.E.); Angiochem, Inc., Montreal, Quebec, Canada (J.E.L.); Pfizer Oncology, San Diego, CA, USA (T.W.J.); Massachusetts Institute of Technology, Cambridge, MA, USA (F.M.W.); US Food and Drug Administration, Silver Spring, MD, USA (J.S.); Texas Tech University School of Pharmacy, Amarillo, TX, USA (Q.R.S., R.S.); NewGen Therapeutics, Inc., Menlo Park, CA, USA (W.S.); Mayo Clinic, Rochester, MN, USA (J.N.S.); Dana-Farber Cancer Institute, Boston, MA, USA (P.Y.W.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (D.A.B.); Celgene Avilomics Research, Bedford, MA, USA (R.C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581696PMC
November 2015

Effect of water solvation on the lipophilicity of isomeric pyrimidine-carboxamides.

Bioorg Med Chem 2015 Jul 22;23(13):3408-13. Epub 2015 Apr 22.

Pfizer Global Research and Development, Department of Chemistry, La Jolla, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2015.04.041DOI Listing
July 2015

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

ACS Med Chem Lett 2013 Jan 7;4(1):91-7. Epub 2012 Nov 7.

Cancer Chemistry, PDM, and Oncology Research Unit, Pfizer Worldwide Research and Development , La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ml300309hDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027523PMC
January 2013

Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.

J Med Chem 2009 Nov;52(22):7211-9

Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm900862nDOI Listing
November 2009

Using the Golden Triangle to optimize clearance and oral absorption.

Bioorg Med Chem Lett 2009 Oct 15;19(19):5560-4. Epub 2009 Aug 15.

Pfizer Global Research and Development, 10770 Science Center Dr., La Jolla, CA 92121, USA.

View Article

Download full-text PDF

Source
https://lundbeck.com/upload/drughunters/2014/pdf/Golden_tria
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S0960894X0901185
Publisher Site
http://dx.doi.org/10.1016/j.bmcl.2009.08.045DOI Listing
October 2009